Published in PLoS One on February 03, 2017
Global cancer statistics. CA Cancer J Clin (2011) 185.92
Global cancer statistics, 2012. CA Cancer J Clin (2015) 53.52
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
External irradiation with or without long-term androgen suppression for prostate cancer with high metastatic risk: 10-year results of an EORTC randomised study. Lancet Oncol (2010) 4.61
The crippling consequences of fractures and their impact on quality of life. Am J Med (1997) 2.98
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol (2005) 2.87
Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol (2011) 2.68
Osteoporosis in men: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab (2012) 1.96
Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol (2002) 1.96
Racial differences in hip axis lengths might explain racial differences in rates of hip fracture. Study of Osteoporotic Fractures Research Group. Osteoporos Int (1994) 1.88
Geographic trends in incidence of hip fractures: a comprehensive literature review. Osteoporos Int (2011) 1.44
Fracture risk following bilateral orchiectomy. J Urol (2003) 1.41
Bone loss following hypogonadism in men with prostate cancer treated with GnRH analogs. J Clin Endocrinol Metab (2002) 1.40
Androgen deprivation therapy: past, present and future. BJU Int (2012) 1.26
EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent. Eur Urol (2016) 1.24
Skeletal morbidity in men with prostate cancer: quality-of-life considerations throughout the continuum of care. Eur Urol (2004) 1.17
Type 2 diabetes and bone fractures. Curr Opin Endocrinol Diabetes Obes (2012) 1.12
Sex steroid hormones in older men: longitudinal associations with 4.5-year change in hip bone mineral density--the osteoporotic fractures in men study. J Clin Endocrinol Metab (2010) 1.04
Androgen deprivation therapy in men with prostate cancer: how should the side effects be monitored and treated? Clin Endocrinol (Oxf) (2011) 0.99
Fracture risk in patients with prostate cancer on androgen deprivation therapy. Osteoporos Int (2005) 0.98
Androgen deprivation therapy as adjuvant/neoadjuvant to radiotherapy for high-risk localised and locally advanced prostate cancer: recent developments. Br J Cancer (2011) 0.94
Secular trends in prostate cancer mortality, incidence and treatment: England and Wales, 1975-2004. BJU Int (2008) 0.92
Racial differences in bone mineral density and fractures in men receiving androgen deprivation therapy for prostate cancer. J Urol (2012) 0.87
Bone mineral density in Japanese prostate cancer patients under androgen-deprivation therapy. Endocr Relat Cancer (2008) 0.85
Trends in the incidence of 15 common cancers in Hong Kong, 1983-2008. Asian Pac J Cancer Prev (2012) 0.82
Androgen deprivation therapy and cardiovascular risk in chinese patients with nonmetastatic carcinoma of prostate. J Oncol (2014) 0.81
Sclerostin serum levels in prostate cancer patients and their relationship with sex steroids. Osteoporos Int (2013) 0.81
Androgen deprivation therapy, diabetes and poor physical performance status increase fracture risk in Chinese men treated for prostate cancer. Aging Male (2015) 0.79
Androgen deprivation increases the risk of fracture in prostate cancer patients: a population-based study in Chinese patients. Osteoporos Int (2015) 0.78
A Randomized Control Trial Comparing the Efficacy of Antiandrogen Monotherapy: Flutamide vs. Bicalutamide. Horm Cancer (2015) 0.77